Melanotan II (MT2): What Is It, How Does It Work and What Are the Risks?

Melanotan II has one feature that sets it apart from many research peptides: there is little doubt that it has obvious effects in humans. Skin becomes darker, nausea is common, yawning and stretching can occur, and spontaneous erections are well documented. So the question about MT2 is not whether the molecule does anything. It clearly does. The questions are whether those effects are safe, predictable and worth the risks of using an unapproved product.

What is Melanotan II?

Melanotan II is a small, ring shaped synthetic peptide designed to mimic part of the natural hormone alpha melanocyte stimulating hormone, alpha-MSH. Alpha-MSH is involved in pigmentation: when it activates melanocortin receptors on the skin's pigment cells, those cells make more melanin, the pigment behind much of the colour of skin and hair. More melanin generally means darker skin, which makes the proposed tanning mechanism fairly straightforward.

Melanotan II is non selective: it activates several melanocortin receptors, including ones that have nothing to do with pigmentation. That is the source of most of its other effects.

Does it actually make skin darker?

Yes. In a pilot phase 1 study published in 1996, three healthy men received injections of Melanotan II alternating with saline over two weeks, and two of them showed darker skin on the face, upper body and buttocks, measured with a skin reflectance meter as well as by eye Human ¹. The same study recorded mild nausea at most doses, drowsiness and tiredness in one man at the highest dose, a stretching and yawning complex, and spontaneous erections lasting one to five hours.

With only three participants the study cannot tell us much about safety. But it did show that Melanotan II is genuinely active in people. It should not be dismissed as fake internet science. The problem is what comes with that activity.

Why does MT2 cause erections?

Because it does not act only on pigment signalling. Melanocortin signalling in the brain also influences sexual behaviour and erections, and researchers investigated Melanotan II as a possible treatment for erectile dysfunction.

In a placebo controlled crossover study of ten men with psychogenic erectile dysfunction, eight had clinically observable erections after Melanotan II Human ². A second study, in men with erectile dysfunction from physical causes, found erections after 12 of 19 injections of the drug against 1 of 21 placebo doses, and more self reported sexual desire, but severe nausea after 4 of the 19 injections ³. Melanotan II itself was never developed into an approved medicine.

Is MT2 the same as PT-141?

No. PT-141, also called bremelanotide, came out of the same melanocortin research and is closely related to Melanotan II, but it is a different molecule. It became a licensed medicine in the US, approved by the FDA in 2019 as Vyleesi for low sexual desire in premenopausal women, not for tanning ⁴. The two should not be treated as interchangeable. A related compound, Melanotan I, became the licensed medicine afamelanotide (Scenesse), authorised in the EU in 2014 to prevent phototoxicity in adults with erythropoietic protoporphyria, a rare light intolerance disorder ⁵. That is a separate story again.

Why does it cause nausea?

The melanocortin system is involved in appetite and brain signalling as well as pigmentation, so a drug that activates several melanocortin receptors at once touches several systems at once. Nausea was frequent in the early studies and severe after 4 of 19 injections in one of them, and yawning and stretching kept appearing. These are not random quirks. They are what happens when a non selective drug switches on more than the one pathway you want, which is exactly why drug developers care about selectivity.

What are the common effects?

The early human studies recorded darker skin, nausea, reduced appetite, yawning, stretching and spontaneous erections. Beyond a tan, case reports describe existing moles enlarging or darkening and new moles appearing ⁶. That list can sound manageable, but it comes from very small trials. The main published human studies of Melanotan II are three small trials, published between 1996 and 2000, with 23 men in total: three in the tanning pilot and ten in each erectile dysfunction study, none lasting more than two weeks. There has never been a trial of it for cosmetic tanning, and none long enough to show what happens over the months or years people actually use it.

What serious problems have been reported?

Case reports have linked Melanotan II to serious medical events. In one, a 39 year old man developed anxiety, a racing heart, sweating, dilated pupils and muscle tremors after injecting a product bought online, followed by severe muscle breakdown (rhabdomyolysis) and impaired kidney function that needed three days of intensive care; mass spectrometry confirmed the injected substance was Melanotan II ⁷. A 2020 case report describes a renal infarction, loss of blood supply to part of a kidney, that its authors judged most likely attributable to Melanotan II ⁸. The FDA, explaining why it considers Melanotan II a significant safety risk in compounding, cites published case reports of melanoma, a sympathomimetic toxidrome, priapism (a painful erection that will not subside) and a brain condition called posterior reversible encephalopathy syndrome ⁹.

Case reports are important warning signs, but they have limits. One case cannot tell you how often something happens, and sometimes it cannot prove the peptide was the cause. The responsible way to put it is that serious adverse events have been reported after Melanotan II use, not that everyone who uses it will have them.

Does Melanotan II cause melanoma?

This needs careful wording. There are published cases of melanoma in people who used Melanotan II. In one, a 20 year old woman with fair skin developed melanoma three months after a short course of injections; she had also used tanning beds ¹⁰. In another, a 42 year old woman's mole on the abdomen enlarged and changed colour over three months after injections, and was confirmed as melanoma on histology ⁶.

Those reports do not prove that Melanotan II caused the melanoma. Sunbeds are themselves a major melanoma risk, and the case literature cannot separate the two. But there are real reasons to be concerned. The drug stimulates the pigment cells that melanoma arises from; it is often used by people with fair skin that tans poorly, the group at highest baseline risk; and because it darkens and changes existing moles, it can make the changes that doctors look for in a developing melanoma harder to spot. The accurate position is that a causal melanoma risk has not been established, but concerning case reports exist and the question is a live one.

Does a Melanotan tan protect against the sun?

A darker look should never be treated as permission for more UV exposure. The NHS is clear that there is no safe or healthy way to get a tan, and that a tan does not protect the skin from the sun's harmful effects; it also warns that sunbeds can be more dangerous than natural sunlight ¹¹. This matters because some people use MT2 alongside sunbeds or strong sun to deepen the effect, which increases UV exposure rather than reducing it.

What about MT2 nasal sprays?

Nasal sprays are often sold as if they were safer than injections. That has not been shown. Changing the route changes how much is absorbed; it does not make an unapproved molecule safe. It also raises a separate question about quality: how much Melanotan II is actually in the bottle? Online products are made without the controls required of licensed medicines, so even precise knowledge of pharmaceutical grade MT2 would say nothing about an online spray.

Is Melanotan II legal in the UK?

No. Melanotan II is not a licensed medicine for any use in the UK. The MHRA says a product containing it is a medicine when it falls within the definition in the Human Medicines Regulations 2012, decided case by case, and must then be authorised before it can legally be sold or supplied. It says it has repeatedly taken action to remove melanotan products from sale for more than ten years, and it received 13 suspected adverse reaction reports linked to Melanotan II through the Yellow Card scheme between 2011 and 2021 ¹². The MHRA also notes that a nasal spray making no medicinal claims will not generally be regulated as a medicine, which is a point about classification, not a sign that such a product is safe. In the US it is not an approved drug, and the FDA lists it among substances that may present significant safety risks in compounding.

Why does the evidence look stronger than for many research peptides?

Because Melanotan II has obvious, measurable effects. Researchers could see pigmentation change, measure erections and record nausea, which makes it easier to study than a peptide claimed to "enhance recovery". But a clear biological effect is not the same as a good medicine. The useful question is always the overall balance. Does the benefit justify the risk? Can the dose be controlled? Is the effect predictable? Is manufacturing reliable? Has the molecule been studied properly? For Melanotan II as a cosmetic tanning agent, no regulator has concluded that the balance is favourable.

The BioRx conclusion

Melanotan II genuinely affects human biology: it can darken skin, suppress appetite and trigger erections through melanocortin signalling. The problem is not that MT2 does not work. It is that working is not the same as being safe or approved. The human studies were tiny, unlicensed products add uncertainty about what is actually in them, and serious harms have been described in case reports. Melanotan II is a biologically active experimental peptide with proven pigmentation effects, but its use as an unlicensed tanning product comes with real uncertainty and documented safety concerns. For something used mainly to change how skin looks, that matters a great deal.

Frequently asked questions

What is Melanotan II?

A synthetic peptide that mimics part of the hormone alpha-MSH and activates melanocortin receptors, darkening the skin. It is sold online as a tanning product but has never been approved as a medicine for that or any other use.

Does Melanotan II work?

It does darken skin: two of three men in the first human study showed visible darkening. It also commonly causes nausea, yawning and spontaneous erections.

Is Melanotan II safe?

Its safety has not been established. The main published human studies total 23 men followed for two weeks at most, and case reports describe serious harms including muscle breakdown, kidney damage and melanoma, although single cases cannot prove cause.

Is Melanotan II legal in the UK?

No. It is not a licensed medicine in the UK, products that count as medicines cannot legally be sold without authorisation, and the MHRA says it has repeatedly acted to remove melanotan products from sale.

Does a Melanotan tan protect against sunburn?

No. There is no safe way to get a tan, and a tan does not protect against the sun's harmful effects.

More peptide questions

References

Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.

1. Dorr RT et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences.PubMed · View study in BioRx
2. Wessells H et al. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. The Journal of Urology.PubMed · View study in BioRx
3. Wessells H et al. (2000). Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology.PubMed · DOI · View study in BioRx
4. FDA, Vyleesi (bremelanotide) approval letter, 2019
5. EMA, Scenesse (afamelanotide) EPAR
6. Paurobally D, Jason F, Dezfoulian B, Nikkels AF (2011). Melanotan-associated melanoma. British Journal of Dermatology.PubMed · DOI · View study in BioRx
7. Nelson ME, Bryant SM, Aks SE (2012). Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology.PubMed · DOI · View study in BioRx
8. Peters B et al. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep 2020
9. FDA, Certain bulk drug substances for use in compounding that may present significant safety risks
10. Hjuler KF, Lorentzen HF (2014). Melanoma associated with the use of melanotan-II. Dermatology.PubMed · DOI · View study in BioRx
11. NHS, Sunscreen and sun safety
12. MHRA, Freedom of Information response on Yellow Card reports for melanotan II products, 2021